Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02789150 · ClinicalTrials.gov registry record · Early Phase 1
Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg
A Early Phase 1 study of Hepatorenal Syndrome, sponsored by University of Louisville.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02789150: Completed Early Phase 1 study of Hepatorenal Syndrome, sponsored by University of Louisville.
NCT02789150 is a Early Phase 1 study of Hepatorenal Syndrome that has completed, run by University of Louisville. The registered enrollment target is 18 participants, below the 421-participant average among 5 other Hepatorenal Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02789150, a Early Phase 1 study of Hepatorenal Syndrome, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Comparing renal outcomes based on a Mean Arterail Pressure (MAP) of 65-7085mmhg versus a MAP of greater than or equal to 85mmhg
Primary Outcome
To determine if High MAP or Low MAP will provide the most optimal renal function. The primary endpoints will be 96h UOP and change in creatinine levels. UOP will be calculated as cc/24 hours. We will compare the change in urinary output of day 1 versus day 4. Creatinine will be measured daily and the change from initiation to completion of the study will be recorded. The mean values of these will be compared.
Conditions Studied
Interventions
- DRUG Norepinephrine (Levophed)
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-01-11 |
| Phase | Early Phase 1 |
What the finished NCT02789150 record still lists
NCT02789150 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 421-participant average among 5 other Hepatorenal Syndrome trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Hepatorenal Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Norepinephrine (Levophed) is the first listed.
NCT02789150 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT02789150 about?
NCT02789150 is a clinical study titled "Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg". Comparing renal outcomes based on a Mean Arterail Pressure (MAP) of 65-7085mmhg versus a MAP of greater than or equal to 85mmhg
What is the current status of trial NCT02789150?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2015-01. Estimated completion is 2018-01-11.
What conditions does trial NCT02789150 study?
This clinical trial studies the following conditions: Hepatorenal Syndrome.
What interventions are being tested in trial NCT02789150?
The interventions under investigation include: Norepinephrine (Levophed) (DRUG).
Who is sponsoring clinical trial NCT02789150?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02789150 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatorenal Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center
RECRUITING
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
COMPLETED · Phase 2
-
Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
COMPLETED · Phase 3
-
International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia